PI Industries Ltd.
NSE: PIINDPI Industries Ltd.: A 30-second snapshot
PI Industries (PIIND) is an agrochemicals and specialty-chemicals company trading at ₹2,775, down 24.6% over the past 12 months and 35.9% from its 52-week high. The stock sits below both the 50-DMA (₹2,956.63) and 200-DMA (₹3,317.89), with 5-year earnings growth of -39.4% and a quality score of 23 that ranks last among six tracked Chemicals peers. Trailing PE is 31.02 against a forward PE of 25.23, with 24 analysts covering the stock at a mean rating of 2.92 on a 1–5 scale (lower = more constructive).
P/E
31.0
Forward P/E
25.2
ROE
+12.3%
Debt / Equity
3.05
Profit Margin
+19.7%
Div. Yield
+0.5%
5Y ROE > 15%
3/5
5Y FCF > 0
3/5
Quality
35/100
News
4 headlines · 0 positive · 2 negative
PI Industries Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - simplywall.st
simplywall.st
PIIND: FY26 revenue and profit declined, but pharma growth and strong margins support a positive FY27 outlook - TradingView
TradingView
ZEE Entertainment, PTC India, PI Industries: Why these stocks fell 6-9% today | Q4 impact - Business Today
Business Today
PI Industries Schedules Analyst and Investor Meetings at Mumbai Conferences - TipRanks
TipRanks
Recent context
- ·Q4 FY26 results missed analyst estimates; a Business Today report noted the stock declined 6-9% on the results day, and SimplyWallSt covered the earnings miss with updated analyst forecasts.
- ·FY26 revenue and profit declined on an annual basis; a TradingView analysis noted that pharma segment growth and margins are cited as supports for a potential FY27 recovery, though no specific targets were given.
- ·PI Industries scheduled analyst and investor meetings at Mumbai conferences in May 2026, suggesting active engagement with institutional coverage at a time when the stock is at a multi-year price low.
Strengths
- +Profit margin of 19.67% remains healthy for the chemicals sector, indicating the company retains meaningful pricing power or cost discipline at the operating level.
- +Forward PE of 25.23 is 19% below the trailing PE of 31.02, reflecting analyst consensus that earnings may recover in the coming year relative to recent depressed levels.
- +Dividend yield of 0.54% is modest but present, suggesting the company has continued shareholder distributions despite a period of earnings pressure.
- +FCF was positive in 3 of the available historical years, and ROE exceeded 15% in 3 of available years, indicating the business has historically generated returns above cost of capital even if that consistency has recently weakened.
Weaknesses
- −5-year earnings growth of -39.4% and 5-year revenue growth of -12.4% reflect multi-year deterioration across both top-line and bottom-line; the trend is not limited to a single quarter.
- −Quality score of 23 places PIIND at the bottom of its 6-stock Chemicals peer group, with closest peer Coromandel International scoring 30 and sector leaders Pidilite Industries and Solar Industries scoring 66 and 61 respectively.
- −Debt-to-equity of 3.048 is elevated and on a rising trend, while ROE of 12.35% falls below the 15% benchmark, raising questions about leverage-adjusted returns as debt continues to increase.
- −Price has declined 24.6% over 12 months and 35.9% from its 52-week high, with the stock trading below both the 50-DMA and 200-DMA and RSI at 36.66 — an extended period of price weakness relative to trend.
Open questions
- ?Does the 19% gap between trailing PE (31.02) and forward PE (25.23) reflect a structural earnings recovery in agrochemicals, or is it driven by one-time items and seasonal tailwinds that may not persist?
- ?Is the rising debt-to-equity trend (now 3.048) accompanied by productive capital deployment — for example, capacity expansion in the pharma CDMO segment — or does it represent working-capital stress from the multi-year revenue decline?
- ?How does PIIND's quality score of 23 versus the peer median of ~44 translate into durable competitive disadvantage, and which specific metrics (ROE, FCF consistency, margin trend) are the primary drag?
- ?The stock is 35.9% below its 52-week high while RSI has not reached oversold levels — what would need to change in the fundamental or macro backdrop (agrochemical cycle, China supply competition) for the price trend to shift direction?
Peer comparison: Chemicals
Ranks 6 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| PIIND | PI Industries Ltd.You're viewing | 31.0 | +12.3% | 23 |
| Industry avg | across 5 peers | 51.6 | +18.0% | 48 |
| PIDILITIND | Pidilite Industries Ltd. | 60.7 | +23.5% | 66 |
| SOLARINDS | Solar Industries India Ltd. | 97.8 | +31.3% | 61 |
| UPL | UPL Ltd. | 28.9 | +5.6% | 44 |
| SRF | SRF Ltd. | 43.5 | +13.8% | 41 |
| COROMANDEL | Coromandel International Ltd. | 27.0 | +15.6% | 30 |
Technical state
Current price
₹2,775.00
SMA 50
₹2,956.63
SMA 200
₹3,317.89
RSI (14)
36.7 (neutral)
From 52w high
-35.9%
1Y return
-24.6%
3M return
-11.0%
50-DMA
Below
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- high5-year earnings growth of -39.4% and 5-year revenue growth of -12.4% reflect sustained multi-year deterioration in both top-line and bottom-line; ROE stands at 12.35%, below the 15% threshold, in only 3 of available years.
- mediumDebt-to-equity of 3.048 with a rising debt trend is elevated for a specialty-chemicals business; FCF positive in only 3 of available years, and the persistence consistency score of 31 (out of 100) is low.
- mediumQuality score of 23 ranks PIIND last (6th of 6) in the Chemicals peer set; peers PIDILITIND, SOLARINDS, SRF, UPL, and COROMANDEL score 66, 61, 41, 44, and 30 respectively.
- mediumPrice of ₹2,775 sits 6.1% below the 50-DMA (₹2,956.63) and 16.4% below the 200-DMA (₹3,317.89); the stock is down 24.6% over 12 months and 35.9% from its 52-week high, remaining below both moving averages.
- lowNews sample is sparse at 4 articles; 2 of 4 carry negative sentiment, including a reported Q4 earnings miss and a single-session decline of 6-9% following results.
Cross-section contradictions
- Forward PE of 25.23 is 19% lower than the trailing PE of 31.02, implying analyst consensus is pricing in a meaningful earnings recovery — yet 5-year earnings growth is -39.4% and Q4 results recently missed analyst estimates.
- RSI of 36.66 is in neutral territory despite a 35.9% drawdown from the 52-week high and price sitting 16.4% below the 200-DMA, an unusual combination where momentum has not reached oversold extremes despite an extended price decline.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 1 Jun 2026 · rotates through NIFTY 500 every ~5 days